E-117 DEMOGRAPHICS, IMAGING FINDINGS, AND DIAGNOSIS IN PATIENTS WITH (POST)COITAL HEADACHES

A Kuhn, J Singh, F Massari, A Puri. Division of Neurointerventional Radiology, Department of Radiology and New England Center for Stroke, University of Massachusetts, Worcester, MA

10.1136/neurintsurg-2022-SNIS.228

Introduction/Purpose To evaluate demographics, imaging findings and final diagnosis in patients presenting with (post)coital headaches.


Results We identified 31 patients (19 women) with a mean age of 44 years (range 23 to 71 years). Mean age at presentation was 49 years for women and 37 years for men. Comorbidities included hypertension, migraine headaches and smoking. Most patients initially underwent cross-sectional imaging (non-contrast CT head and CT angiogram or MRI head and MR angiogram). A bleed was identified in 6 cases (31.6%, 4 women and 2 men) with subarachnoid hemorrhage (SAH) in 4 cases, intraventricular hemorrhage (IVH) in 1 case and a combination of SAH and IVH in 1 case. Intracranial bleeds were secondary to ruptured cerebral aneurysms in 3 cases, non-aneurysmal perimesencephalic SAH in 2 cases and intracranial venous congestion in 1 case. Other findings without intracranial hemorrhage included incidental, unruptured cerebral aneurysms in 4 cases (all women), a carotid dissection in 1 case and reversible cerebral vasospasmstic syndrome in 1 case (both women). The remaining of the patients (n=19) did not show any imaging findings.

Conclusion (Post)coital headaches can be due to acute intracranial hemorrhage which may have a serious underlying cause such as a ruptured brain aneurysm. Women more commonly demonstrate an underlying vascular pathology. Cross-sectional imaging, including vascular imaging, is helpful in these patients to exclude the need for emergent intervention and to guide further management.

Disclosures A. Kuhn: None. J. Singh: None. F. Massari: None. A. Puri: 1; C; NIH, Microvention, Cerenovus, Medtronic Neurovascular and Stryker Neurovascular. 2; C; Medtronic Neurovascular, Stryker NeurovascularBalt, Q’Apel Medical, Cerenovus, Microvention, Imperative Care, Agile, Merit, CereVasc and Arsenal Medical. 4; C; InNeuroCo, Agile, Perfuze, Galaxy and NTI.

E-118 COATING STUDY: A RCT EVALUATING THE COATED FLOW DIVERTER P64-MW-HPC

L Pierot, 1Lamin, 2C Cognard, 1L Spelle. 1Neuroradiology, Hôpital Maison-Blanche, Reims, FRANCE; 2Neuroradiology, University Hospital Birmingham – Queen Elizabeth Hospital, Birmingham, UK; 3Neuroradiology, CHU Toulouse, Toulouse, FRANCE; 4Neuroradiology, Hôpital Kremlin-Bicêtre, Kremlin-Bicêtre, FRANCE

10.1136/neurintsurg-2022-SNIS.229

Introduction/Purpose Flow Diversion is increasingly used for the treatment of intracranial aneurysms due to its high efficacy. However its us is still restricted to unruptured and recanalized aneurysms due to the need of a dual antiplatelet therapy to prevent thromboembolic complications. P64-MW-HPC (phenox, Bochum, Germany) is a coated flow diverter. Hydrophilic Polymer Coating (HPC) is a glycolalyx-like glycans based polymer covalently bonded to the surface of the p64 flow diverter, which is supposed to reduce platelet aggregation. COATING is a RCT dedicated to the comparative evaluation of this coated flow diverter.

Materials and Methods COATING is a RCT comparing the rate of thromboembolic complications in patients treated with bare p64-MW under dual antiplatelet treatment and patients treated with coated p64-MW-HPC under single anti platelet treatment. The primary safety endpoint is the number of Diffusion-weighted Imaging lesions depicted within 48 hours (+/- 24 hours) of the index procedure by 3T-MRI. COATING study is conducted in 14 Interventional Neuroradiology centers in Europe (France, Germany, Italy, United Kingdom). The population of the study will be 170 patients (85 per arm. An interim analysis will be conducted after inclusion of 50% of the population.

Results A detailed presentation of the COATING protocol as well as the status of inclusions at the time of presentation will be presented.

Conclusions COATING study is the first comparative study to properly evaluate a coated flow diverter. The results of this study will potentially change the indications of flow diversion of the endovascular treatment of intracranial aneurysms.

Disclosures L. Pierot: 2; C; Balt, Microvention, Phenox, Perflow, Vesalio. S. Lamin: None. C. Cognard: None. L. Spelle: None.